Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Sep 30

PMID 32992444

Citations 2

Authors

Renate Pichler

Affiliations

Soon will be listed here.

Abstract

Bladder cancer and renal cell carcinoma (RCC) are the second and third most commonly diagnosed cancers in the field of uro-oncology [...].

Citing Articles

Identification of Novel Prognostic Signatures for Clear Cell Renal Cell Carcinoma Based on ceRNA Network Construction and Immune Infiltration Analysis.

Zhou L, Ye J, Wen F, Yu H Dis Markers. 2022; 2022:4033583.

PMID: 35320950 PMC: 8938059. DOI: 10.1155/2022/4033583.

Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.

Su Y, Zhang T, Tang J, Zhang L, Fan S, Zhou J Front Oncol. 2021; 11:640150.

PMID: 33869028 PMC: 8044754. DOI: 10.3389/fonc.2021.640150.

References

Choueiri T, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P . Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018; 19(4):451-460. DOI: 10.1016/S1470-2045(18)30107-4. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

Choueiri T, Halabi S, Sanford B, Hahn O, Michaelson M, Walsh M . Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017; 35(6):591-597. PMC: 5455807. DOI: 10.1200/JCO.2016.70.7398. View

Heery C, OSullivan-Coyne G, Madan R, Cordes L, Rajan A, Rauckhorst M . Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017; 18(5):587-598. PMC: 6387686. DOI: 10.1016/S1470-2045(17)30239-5. View

Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D . Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1116-1127. DOI: 10.1056/NEJMoa1816714. View

Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K . Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017; 8(1):2193. PMC: 5736752. DOI: 10.1038/s41467-017-02320-7. View

Robertson A, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack A . Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017; 171(3):540-556.e25. PMC: 5687509. DOI: 10.1016/j.cell.2017.09.007. View

Motzer R, Penkov K, Haanen J, Rini B, Albiges L, Campbell M . Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1103-1115. PMC: 6716603. DOI: 10.1056/NEJMoa1816047. View

Tannir N, Signoretti S, Choueiri T, Mcdermott D, Motzer R, Flaifel A . Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2020; 27(1):78-86. PMC: 8589223. DOI: 10.1158/1078-0432.CCR-20-2063. View

10.

Galsky M, Arranz Arija J, Bamias A, Davis I, De Santis M, Kikuchi E . Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395(10236):1547-1557. DOI: 10.1016/S0140-6736(20)30230-0. View

11.

Wallin J, Bendell J, Funke R, Sznol M, Korski K, Jones S . Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016; 7:12624. PMC: 5013615. DOI: 10.1038/ncomms12624. View

12.

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

13.

Bellmunt J, Petrylak D . New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012; 39(5):598-607. DOI: 10.1053/j.seminoncol.2012.08.007. View

14.

. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492):315-22. PMC: 3962515. DOI: 10.1038/nature12965. View

15.

Powles T, Park S, Voog E, Caserta C, Valderrama B, Gurney H . Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020; 383(13):1218-1230. DOI: 10.1056/NEJMoa2002788. View

16.

Grimm M, Bex A, De Santis M, Ljungberg B, Catto J, Roupret M . Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. Eur Urol. 2019; 76(3):368-380. DOI: 10.1016/j.eururo.2019.05.041. View

17.

Barata P, Koshkin V, Funchain P, Sohal D, Pritchard A, Klek S . Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017; 28(10):2458-2463. DOI: 10.1093/annonc/mdx405. View

18.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

19.

Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018; 24(6):749-757. PMC: 6721896. DOI: 10.1038/s41591-018-0053-3. View